Disclosed herein are processes for preparing 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one and FGFR inhibitor, as well as polymorphs and/or salt forms thereof.

Disclosed herein are processes for preparing 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one and FGFR inhibitor, as well as polymorphs and/or salt forms thereof.

In the presence of a catalyst and a cycloalkane compound represented by formula (3):

##STR00001##

wherein R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10 are the same or different and each is a halogen atom, an alkyl group, or a fluoroalkyl group; an alkene compound represented by formula (2):

##STR00002##

wherein X.sup.1, X.sup.2, R.sup.1, and R.sup.2 are as defined above; is reacted with a hydrogen-containing gas to hydrogenate the alkene compound represented by formula (2), whereby an alkane compound represented by R.sup.1CHX.sup.1CHX.sup.2R.sup.2, wherein X.sup.1 and X.sup.2 are the same or different and each is a halogen atom, and R.sup.1 and R.sup.2 are the same or different and each is an alkyl group or a fluoroalkyl group; can be synthesized in such a manner that (S), (R)-isomer, (R), (R)-isomer, and (S), (S)-isomer are co-produced.